share_log
Breakings ·  Nov 15 19:59
Bristol Myers Squibb Receives Positive Chmp Opinion for Repotrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer and Advanced Ntrk-Positive Solid Tumors
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment